Prognostic value of programmed cell death ligand-1 expression in ovarian cancer: an updated meta-analysis
Jinlan Piao, Hyun Ji Lim, Maria Lee
Obstet Gynecol Sci. 2020;63(3):346-356.   Published online 2020 Mar 24     DOI: https://doi.org/10.5468/ogs.2020.63.3.346
Citations to this article as recorded by Crossref logo
PD-L1 expression with QR1 and E1L3N antibodies according to histological ovarian cancer subtype: A series of 232 cases
Caroline Eymerit-Morin, Anna Ilenko, Thomas Gaillard, Justine Varinot, Eva Compérat, Sofiane Bendifallah, Emile Darai
European Journal of Histochemistry.2021;[Epub]     CrossRef
Intersection of DNA Repair Pathways and the Immune Landscape Identifies PD-L2 as a Prognostic Marker in Epithelial Ovarian Cancer
Samantha Batman, Koji Matsuo, Paulette Mhawech-Fauceglia, Elizabeth Munro, Mercedes Weisenberger, Allison Allen, Sonali Joshi, Hiroko Machida, Shinya Matsuzaki, Tatjana Bozanovic, Tanja Pejovic
Cancers.2021; 13(8): 1972.     CrossRef
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
Margherita Turinetto, Giulia Scotto, Valentina Tuninetti, Gaia Giannone, Giorgio Valabrega
Frontiers in Oncology.2021;[Epub]     CrossRef
The role of immunotherapy in the management of metastatic/recurrent female reproductive system neoplasms
A. A. Rumyantsev, A. Yu. Anokhin
Meditsinskiy sovet = Medical Council.2021; (9): 76.     CrossRef